New heart device made available through FDA expanded access
NCT ID NCT07421557
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program allows patients to receive Occlutech's atrial flow regulator, a device implanted via catheter to help control blood flow between the upper chambers of the heart. It is available under the FDA's Expanded Access program for those who meet eligibility criteria. The goal is to provide access to this device for patients who may not have other treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Occlutech atrial flow regulator device
- What this could lead to
- If successful, this device may help manage certain heart conditions by regulating blood flow between the atria.
- What could go wrong
- This is an expanded access program, not a formal trial, so data on safety and effectiveness are limited. The device may not work for all patients and carries procedural risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new related studies are added.
By submitting, you agree to our Terms of use
Contacts and locations
Locations
-
Individual Sites Across the U.S.
AVAILABLEMaple Grove, Minnesota, 55369, United States